Introduction: Postprandial hyperglycemia (PPHG) contributes to micro-and macro-vascular
complications more than fasting hyperglycemia in patients with type 2 diabetes mellitus. Due …

Objective To provide an overview of the disease burden and current strategies in the
treatment of patients with type 2 diabetes. Data sources Medline search of all relevant …

This study investigated the long-term efficacy and safety of empagliflozin as add-on to
metformin plus sulphonylurea in patients with type 2 diabetes mellitus (T2DM). Of 666 …

Background Citrus bioflavonoids are polyphenolic compounds that are derived from citrus
fruits and vegetables. Although they are well known for their powerful antioxidant properties …

Incretin‐based therapies encompass two new classes of antidiabetic drugs: glucagon‐like
peptide‐1 (GLP‐l) receptor agonists (eg, liraglutide, exenatide, and exenatide long‐acting …

Abstract Aims/Introduction To assess the time to initiation of insulin therapy, and concurrently
investigate both patient‐and physician‐related factors associated with delaying insulin …

Standard therapies for type 2 diabetes often fail to maintain glycemic control over the long
term, in part because they do not target the underlying cause. Current treatments may also …

Type 2 diabetes is a progressive disease in which beta-cell function continually declines
and eventually fails, ultimately requiring nearly all patients to be placed on insulin therapy …

Currently available antihyperglycemic agents, despite being effective, provide inadequate
glycemic control and/or are associated with side effects or nonadherence. Canagliflozin, a …

The clinical response to sulphonylurea, an oral antidiabetic agent often used in combination
with metformin to control blood glucose in type 2 diabetes (T2DM) patients, has been widely …